BioElectronics（BIEL）株式概要バイオエレクトロニクス・コーポレーションは、神経疾患を緩和し、生活の質を向上させるためのウェアラブル・ニューロモジュレーション・デバイスの開発と販売を世界中で行っている。 詳細BIEL ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析US市場と比較して、過去 3 か月間の株価の変動が非常に大きい最新の財務報告は1年以上前のものである 意味のある時価総額がありません ( $10M )すべてのリスクチェックを見るBIEL Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.0004207.7% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-3m2m2016201920222025202620282031Revenue US$1.6mEarnings US$214.4kAdvancedSet Fair ValueView all narrativesBioElectronics Corporation 競合他社Scientific IndustriesSymbol: OTCPK:SCNDMarket cap: US$9.1mSintx TechnologiesSymbol: NasdaqCM:SINTMarket cap: US$9.5mCo-DiagnosticsSymbol: NasdaqCM:CODXMarket cap: US$13.4mBiomericaSymbol: NasdaqCM:BMRAMarket cap: US$7.5m価格と性能株価の高値、安値、推移の概要BioElectronics過去の株価現在の株価US$0.000452週高値US$0.001452週安値US$0.0001ベータ01ヶ月の変化8.11%3ヶ月変化0%1年変化100.00%3年間の変化14.29%5年間の変化-86.21%IPOからの変化-99.90%最新ニュースお知らせ • Dec 03BioElectronics Corporation Appoints Sree Koneru to Its Board of DirectorsBioElectronics Corporation announced that Sree Koneru, PhD, will join its Board of Directors, effective December 3, 2024. Upon Dr. Koneru’s appointment, the Board will consist of three members, including Kelly Whelan, President of BioElectronics, and its Chairman, Richard Staelin, PhD. Dr. Koneru is Director of Program Management for a contract manufacturing organization that specializes in the design & development of wearable and implantable active electronic medical devices. In his previous role, Sree served as the VP of Product Development for BioElectronics Corporation, where he was responsible for prototype development, physiological testing/clinical evaluation, and regulatory submissions, culminating in several approvals from the US FDA and a CE marking. He also managed the product life cycle from conception to retail launch for domestic and international channel partners. Sree obtained his doctoral degree in Biomedical Engineering ('15) from the State University of New York at Binghamton, NY- USA. He has a background in bringing Neuromodulation (Electroceuticals) medical devices to market, with research expertise in investigating physiological responses (prototype development and clinical research) of pulsed radiofrequency electromagnetic fields. His vision is to be an industry leader in developing transcutaneous, percutaneous, implantable, and electromagnetic neuromodulation technologies, intended to treat chronic diseases.お知らせ • Mar 27BioElectronics Corporation Announces the Results and Publication of A Canine Arthritis StudyBioElectronics Corporation announced the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy (PSWT) device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed either increased passive range of motion, improved behavioral changes, or both compared to 4% for the placebo group. A randomized, blinded, placebo-controlled 14-day study of 60 dogs having prior veterinary-diagnosis OA in at least one limb joint. Two outcomes measuring the dog's quality of life were assessed: subjectively determined changes in eight behaviors associated with discomfort, and objectively determined changes in passive range of motion (PROM). BioElectronics' Model 088 device was secured near the cervical region of the dog's spine. PROM measures were taken at baseline and day 14. Behavioral measures were taken daily. Forty-nine animals completed the study. No negative side effects were reported. Average subjective discomfort scores for the treatment group (N=26) were reduced from 4.26 to 2.31 (45%) compared to no improvement in the placebo group (N=23) over the study period. Average PROM scores increased by 5.51 (4.59--6.23) degrees relative to the placebo group. Most changes occurred within the first 8 days of treatment. Osteoarthritis is the most common type of arthritis in dogs and is the most common source of chronic pain in older dogs. This is due to the constant wearing away of the cartilage from dogs running, jumping, and other continuous exercise. The prevalence of osteoarthritis can be as high as 20% in dogs more than a year old, with middle-aged and older dogs being at higher risk. dogs that are diagnosed with arthritis tend to be lethargic, have difficulty moving from a sitting or lying position, cracking joints, stiffness, muscle wastage, and visible pain. Current treatment options for arthritis are typically NSAIDs given alone or in combination with other disease-modifying agents. In recent years, chronic use of NSAIDs has been linked to numerous side effects, including gastrointestinal (GI) bleeding, and renal and hepatic dysfunction. Anti-inflammatory drugs such aspirin and ibuprofen may also result in side effects, such as GI bleeding. BioElectronics Model 088 applied at the cervical spine level, may have the potential to significantly improve the quality of life for dogs and other small domestic animals with OA. Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device into the veterinary medicine market.お知らせ • Feb 23Bioelectronics Corporation Announces the Publication of Pilot Study ResultsBioElectronics Corporation announced the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device. The study design had patients first wear BioElectronics' Model 088 device (about 1/2 wearing the sham device and the remaining wearing the active device) on the residual part of the limb for 28 days. After 28 days, the patient began wearing the opposite device, i.e., the sham group wearing the active device, and the treatment group wearing the active device, again for 28 days. Three major measures were obtained for both phantom pain and residual pain along with a global assessment of change in both phantom and residual pain before, during, and after each 28 days. The researchers presented their findings in a series of graphs over time depending on whether the patient was wearing the sham or active device. When wearing the sham device, patients reported, on average, no change in the median phantom limb pain or pain in the residual limb. They also reported no median change in their global assessment of pain. In contrast, when the patients were wearing the active device, they reported, on average, a 40% to 50% decrease in the median measures for both average and worst residual and phantom limb pain by day 7 and this reduction continued through day 28. Moreover, a majority of patients, when wearing the active device, reported the highest level of global change in residual pain, i.e., "very much better" by day 21 and this continued through day 28. This measure on the phantom limb pain was also positive, with the majority of subjects reporting being " much better". The researchers conclude that further study is warranted given that an identified beneficial treatment effect is associated with using BioElectronics' Model 0 88 in the setting of a low-cost and low-risk intervention. Currently, there are 1.6 million people in the United States who are living with the loss of a limb. Due to the rising number of people who have diabetes, a major cause of amputations, it is estimated that the number of amputations could grow to as many as 3.6 million by 2050. More than 7 in 10 people who have had an arm or leg amputated have pain in the lost limb, which they perceive as still present. Nearly 4 in 10 have severe pain, and many also report depression and anxiety linked with phantom limb pain making it hard to sleep, work, and take part in family and social activities. People who have phantom limb pain are often prescribed medications, including opioids, but opioid medications are effective in only about half of these patients and can also have serious side effects, including the risk of addiction. Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device to address this significant unmet medical need.お知らせ • Dec 17BioElectronics Executes Distribution Agreement with KT Health, LLC for North American Retail MarketBioElectronics Corporation announced that it has executed an OEM agreement with KT Health, LLC to bring its innovative pain management devices to encompass retail and e-commerce distribution throughout North America, as well as several additional key international markets.お知らせ • Nov 07BioElectronics' ActiPatch Therapy To Be Marketed By DonJoy AdvantageBioElectronics Corporation announced the execution of a commercial partnership agreement with Scott Specialties Inc. to bring their innovative pain management devices to the retail consumer healthcare marketplace under the DonJoy (DJO www.djoglobal.com) Advantage product line. This commercial partnership will leverage the ActiPatch's broad indications for use and offer an active-passive treatment combination product to treat pain, increase physical functionality and improve overall quality of life. The new products will be marketed under DJO's DonJoy Advantage (DJA) line of orthopedic appliances and sold as an EME Knee Wrap and an EME Back Wrap," powered by ActiPatch".最新情報をもっと見るRecent updatesお知らせ • Dec 03BioElectronics Corporation Appoints Sree Koneru to Its Board of DirectorsBioElectronics Corporation announced that Sree Koneru, PhD, will join its Board of Directors, effective December 3, 2024. Upon Dr. Koneru’s appointment, the Board will consist of three members, including Kelly Whelan, President of BioElectronics, and its Chairman, Richard Staelin, PhD. Dr. Koneru is Director of Program Management for a contract manufacturing organization that specializes in the design & development of wearable and implantable active electronic medical devices. In his previous role, Sree served as the VP of Product Development for BioElectronics Corporation, where he was responsible for prototype development, physiological testing/clinical evaluation, and regulatory submissions, culminating in several approvals from the US FDA and a CE marking. He also managed the product life cycle from conception to retail launch for domestic and international channel partners. Sree obtained his doctoral degree in Biomedical Engineering ('15) from the State University of New York at Binghamton, NY- USA. He has a background in bringing Neuromodulation (Electroceuticals) medical devices to market, with research expertise in investigating physiological responses (prototype development and clinical research) of pulsed radiofrequency electromagnetic fields. His vision is to be an industry leader in developing transcutaneous, percutaneous, implantable, and electromagnetic neuromodulation technologies, intended to treat chronic diseases.お知らせ • Mar 27BioElectronics Corporation Announces the Results and Publication of A Canine Arthritis StudyBioElectronics Corporation announced the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy (PSWT) device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed either increased passive range of motion, improved behavioral changes, or both compared to 4% for the placebo group. A randomized, blinded, placebo-controlled 14-day study of 60 dogs having prior veterinary-diagnosis OA in at least one limb joint. Two outcomes measuring the dog's quality of life were assessed: subjectively determined changes in eight behaviors associated with discomfort, and objectively determined changes in passive range of motion (PROM). BioElectronics' Model 088 device was secured near the cervical region of the dog's spine. PROM measures were taken at baseline and day 14. Behavioral measures were taken daily. Forty-nine animals completed the study. No negative side effects were reported. Average subjective discomfort scores for the treatment group (N=26) were reduced from 4.26 to 2.31 (45%) compared to no improvement in the placebo group (N=23) over the study period. Average PROM scores increased by 5.51 (4.59--6.23) degrees relative to the placebo group. Most changes occurred within the first 8 days of treatment. Osteoarthritis is the most common type of arthritis in dogs and is the most common source of chronic pain in older dogs. This is due to the constant wearing away of the cartilage from dogs running, jumping, and other continuous exercise. The prevalence of osteoarthritis can be as high as 20% in dogs more than a year old, with middle-aged and older dogs being at higher risk. dogs that are diagnosed with arthritis tend to be lethargic, have difficulty moving from a sitting or lying position, cracking joints, stiffness, muscle wastage, and visible pain. Current treatment options for arthritis are typically NSAIDs given alone or in combination with other disease-modifying agents. In recent years, chronic use of NSAIDs has been linked to numerous side effects, including gastrointestinal (GI) bleeding, and renal and hepatic dysfunction. Anti-inflammatory drugs such aspirin and ibuprofen may also result in side effects, such as GI bleeding. BioElectronics Model 088 applied at the cervical spine level, may have the potential to significantly improve the quality of life for dogs and other small domestic animals with OA. Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device into the veterinary medicine market.お知らせ • Feb 23Bioelectronics Corporation Announces the Publication of Pilot Study ResultsBioElectronics Corporation announced the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device. The study design had patients first wear BioElectronics' Model 088 device (about 1/2 wearing the sham device and the remaining wearing the active device) on the residual part of the limb for 28 days. After 28 days, the patient began wearing the opposite device, i.e., the sham group wearing the active device, and the treatment group wearing the active device, again for 28 days. Three major measures were obtained for both phantom pain and residual pain along with a global assessment of change in both phantom and residual pain before, during, and after each 28 days. The researchers presented their findings in a series of graphs over time depending on whether the patient was wearing the sham or active device. When wearing the sham device, patients reported, on average, no change in the median phantom limb pain or pain in the residual limb. They also reported no median change in their global assessment of pain. In contrast, when the patients were wearing the active device, they reported, on average, a 40% to 50% decrease in the median measures for both average and worst residual and phantom limb pain by day 7 and this reduction continued through day 28. Moreover, a majority of patients, when wearing the active device, reported the highest level of global change in residual pain, i.e., "very much better" by day 21 and this continued through day 28. This measure on the phantom limb pain was also positive, with the majority of subjects reporting being " much better". The researchers conclude that further study is warranted given that an identified beneficial treatment effect is associated with using BioElectronics' Model 0 88 in the setting of a low-cost and low-risk intervention. Currently, there are 1.6 million people in the United States who are living with the loss of a limb. Due to the rising number of people who have diabetes, a major cause of amputations, it is estimated that the number of amputations could grow to as many as 3.6 million by 2050. More than 7 in 10 people who have had an arm or leg amputated have pain in the lost limb, which they perceive as still present. Nearly 4 in 10 have severe pain, and many also report depression and anxiety linked with phantom limb pain making it hard to sleep, work, and take part in family and social activities. People who have phantom limb pain are often prescribed medications, including opioids, but opioid medications are effective in only about half of these patients and can also have serious side effects, including the risk of addiction. Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device to address this significant unmet medical need.お知らせ • Dec 17BioElectronics Executes Distribution Agreement with KT Health, LLC for North American Retail MarketBioElectronics Corporation announced that it has executed an OEM agreement with KT Health, LLC to bring its innovative pain management devices to encompass retail and e-commerce distribution throughout North America, as well as several additional key international markets.お知らせ • Nov 07BioElectronics' ActiPatch Therapy To Be Marketed By DonJoy AdvantageBioElectronics Corporation announced the execution of a commercial partnership agreement with Scott Specialties Inc. to bring their innovative pain management devices to the retail consumer healthcare marketplace under the DonJoy (DJO www.djoglobal.com) Advantage product line. This commercial partnership will leverage the ActiPatch's broad indications for use and offer an active-passive treatment combination product to treat pain, increase physical functionality and improve overall quality of life. The new products will be marketed under DJO's DonJoy Advantage (DJA) line of orthopedic appliances and sold as an EME Knee Wrap and an EME Back Wrap," powered by ActiPatch".株主還元BIELUS Medical EquipmentUS 市場7D-11.1%3.0%-0.8%1Y100.0%-18.3%27.1%株主還元を見る業界別リターン: BIEL過去 1 年間で-18.3 % の収益を上げたUS Medical Equipment業界を上回りました。リターン対市場: BIEL過去 1 年間で27.1 % の収益を上げたUS市場を上回りました。価格変動Is BIEL's price volatile compared to industry and market?BIEL volatilityBIEL Average Weekly Movement38.4%Medical Equipment Industry Average Movement8.6%Market Average Movement7.2%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.2%安定した株価: BIELの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: BIELの 週次ボラティリティ は過去 1 年間で61%から38%に減少しましたが、依然としてUS株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2000n/aKelly Whelanwww.bielcorp.comバイオエレクトロニクス・コーポレーションは、神経疾患の緩和と生活の質の向上を目的としたウェアラブル神経調節デバイスの開発と販売を世界中で行っている。同社の製品には、筋骨格系疼痛治療薬ActiPatch、月経痛治療薬Allay、踵痛治療薬Smart Insoleなどがある。また、医療従事者向けに疼痛管理療法を提供する医療機器RecoveryRxや、腫れや痛みを軽減し、筋肉や腱の損傷、ただれ、切開を治癒する馬、猫、犬用の薬物不使用療法HealFastも提供している。卸売業者、病院、診療所、消費者に製品を販売している。同社は2000年に法人化され、メリーランド州フレデリックに本社を置いている。もっと見るBioElectronics Corporation 基礎のまとめBioElectronics の収益と売上を時価総額と比較するとどうか。BIEL 基礎統計学時価総額US$9.88m収益（TTM）-US$289.82k売上高(TTM)US$1.61m0.0xP/Sレシオ0.0xPER（株価収益率BIEL は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BIEL 損益計算書（TTM）収益US$1.61m売上原価US$813.93k売上総利益US$795.53kその他の費用US$1.09m収益-US$289.82k直近の収益報告Dec 31, 2021次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%BIEL の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 02:34終値2026/05/22 00:00収益2021/12/31年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BioElectronics Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Dec 03BioElectronics Corporation Appoints Sree Koneru to Its Board of DirectorsBioElectronics Corporation announced that Sree Koneru, PhD, will join its Board of Directors, effective December 3, 2024. Upon Dr. Koneru’s appointment, the Board will consist of three members, including Kelly Whelan, President of BioElectronics, and its Chairman, Richard Staelin, PhD. Dr. Koneru is Director of Program Management for a contract manufacturing organization that specializes in the design & development of wearable and implantable active electronic medical devices. In his previous role, Sree served as the VP of Product Development for BioElectronics Corporation, where he was responsible for prototype development, physiological testing/clinical evaluation, and regulatory submissions, culminating in several approvals from the US FDA and a CE marking. He also managed the product life cycle from conception to retail launch for domestic and international channel partners. Sree obtained his doctoral degree in Biomedical Engineering ('15) from the State University of New York at Binghamton, NY- USA. He has a background in bringing Neuromodulation (Electroceuticals) medical devices to market, with research expertise in investigating physiological responses (prototype development and clinical research) of pulsed radiofrequency electromagnetic fields. His vision is to be an industry leader in developing transcutaneous, percutaneous, implantable, and electromagnetic neuromodulation technologies, intended to treat chronic diseases.
お知らせ • Mar 27BioElectronics Corporation Announces the Results and Publication of A Canine Arthritis StudyBioElectronics Corporation announced the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy (PSWT) device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed either increased passive range of motion, improved behavioral changes, or both compared to 4% for the placebo group. A randomized, blinded, placebo-controlled 14-day study of 60 dogs having prior veterinary-diagnosis OA in at least one limb joint. Two outcomes measuring the dog's quality of life were assessed: subjectively determined changes in eight behaviors associated with discomfort, and objectively determined changes in passive range of motion (PROM). BioElectronics' Model 088 device was secured near the cervical region of the dog's spine. PROM measures were taken at baseline and day 14. Behavioral measures were taken daily. Forty-nine animals completed the study. No negative side effects were reported. Average subjective discomfort scores for the treatment group (N=26) were reduced from 4.26 to 2.31 (45%) compared to no improvement in the placebo group (N=23) over the study period. Average PROM scores increased by 5.51 (4.59--6.23) degrees relative to the placebo group. Most changes occurred within the first 8 days of treatment. Osteoarthritis is the most common type of arthritis in dogs and is the most common source of chronic pain in older dogs. This is due to the constant wearing away of the cartilage from dogs running, jumping, and other continuous exercise. The prevalence of osteoarthritis can be as high as 20% in dogs more than a year old, with middle-aged and older dogs being at higher risk. dogs that are diagnosed with arthritis tend to be lethargic, have difficulty moving from a sitting or lying position, cracking joints, stiffness, muscle wastage, and visible pain. Current treatment options for arthritis are typically NSAIDs given alone or in combination with other disease-modifying agents. In recent years, chronic use of NSAIDs has been linked to numerous side effects, including gastrointestinal (GI) bleeding, and renal and hepatic dysfunction. Anti-inflammatory drugs such aspirin and ibuprofen may also result in side effects, such as GI bleeding. BioElectronics Model 088 applied at the cervical spine level, may have the potential to significantly improve the quality of life for dogs and other small domestic animals with OA. Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device into the veterinary medicine market.
お知らせ • Feb 23Bioelectronics Corporation Announces the Publication of Pilot Study ResultsBioElectronics Corporation announced the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device. The study design had patients first wear BioElectronics' Model 088 device (about 1/2 wearing the sham device and the remaining wearing the active device) on the residual part of the limb for 28 days. After 28 days, the patient began wearing the opposite device, i.e., the sham group wearing the active device, and the treatment group wearing the active device, again for 28 days. Three major measures were obtained for both phantom pain and residual pain along with a global assessment of change in both phantom and residual pain before, during, and after each 28 days. The researchers presented their findings in a series of graphs over time depending on whether the patient was wearing the sham or active device. When wearing the sham device, patients reported, on average, no change in the median phantom limb pain or pain in the residual limb. They also reported no median change in their global assessment of pain. In contrast, when the patients were wearing the active device, they reported, on average, a 40% to 50% decrease in the median measures for both average and worst residual and phantom limb pain by day 7 and this reduction continued through day 28. Moreover, a majority of patients, when wearing the active device, reported the highest level of global change in residual pain, i.e., "very much better" by day 21 and this continued through day 28. This measure on the phantom limb pain was also positive, with the majority of subjects reporting being " much better". The researchers conclude that further study is warranted given that an identified beneficial treatment effect is associated with using BioElectronics' Model 0 88 in the setting of a low-cost and low-risk intervention. Currently, there are 1.6 million people in the United States who are living with the loss of a limb. Due to the rising number of people who have diabetes, a major cause of amputations, it is estimated that the number of amputations could grow to as many as 3.6 million by 2050. More than 7 in 10 people who have had an arm or leg amputated have pain in the lost limb, which they perceive as still present. Nearly 4 in 10 have severe pain, and many also report depression and anxiety linked with phantom limb pain making it hard to sleep, work, and take part in family and social activities. People who have phantom limb pain are often prescribed medications, including opioids, but opioid medications are effective in only about half of these patients and can also have serious side effects, including the risk of addiction. Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device to address this significant unmet medical need.
お知らせ • Dec 17BioElectronics Executes Distribution Agreement with KT Health, LLC for North American Retail MarketBioElectronics Corporation announced that it has executed an OEM agreement with KT Health, LLC to bring its innovative pain management devices to encompass retail and e-commerce distribution throughout North America, as well as several additional key international markets.
お知らせ • Nov 07BioElectronics' ActiPatch Therapy To Be Marketed By DonJoy AdvantageBioElectronics Corporation announced the execution of a commercial partnership agreement with Scott Specialties Inc. to bring their innovative pain management devices to the retail consumer healthcare marketplace under the DonJoy (DJO www.djoglobal.com) Advantage product line. This commercial partnership will leverage the ActiPatch's broad indications for use and offer an active-passive treatment combination product to treat pain, increase physical functionality and improve overall quality of life. The new products will be marketed under DJO's DonJoy Advantage (DJA) line of orthopedic appliances and sold as an EME Knee Wrap and an EME Back Wrap," powered by ActiPatch".
お知らせ • Dec 03BioElectronics Corporation Appoints Sree Koneru to Its Board of DirectorsBioElectronics Corporation announced that Sree Koneru, PhD, will join its Board of Directors, effective December 3, 2024. Upon Dr. Koneru’s appointment, the Board will consist of three members, including Kelly Whelan, President of BioElectronics, and its Chairman, Richard Staelin, PhD. Dr. Koneru is Director of Program Management for a contract manufacturing organization that specializes in the design & development of wearable and implantable active electronic medical devices. In his previous role, Sree served as the VP of Product Development for BioElectronics Corporation, where he was responsible for prototype development, physiological testing/clinical evaluation, and regulatory submissions, culminating in several approvals from the US FDA and a CE marking. He also managed the product life cycle from conception to retail launch for domestic and international channel partners. Sree obtained his doctoral degree in Biomedical Engineering ('15) from the State University of New York at Binghamton, NY- USA. He has a background in bringing Neuromodulation (Electroceuticals) medical devices to market, with research expertise in investigating physiological responses (prototype development and clinical research) of pulsed radiofrequency electromagnetic fields. His vision is to be an industry leader in developing transcutaneous, percutaneous, implantable, and electromagnetic neuromodulation technologies, intended to treat chronic diseases.
お知らせ • Mar 27BioElectronics Corporation Announces the Results and Publication of A Canine Arthritis StudyBioElectronics Corporation announced the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy (PSWT) device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed either increased passive range of motion, improved behavioral changes, or both compared to 4% for the placebo group. A randomized, blinded, placebo-controlled 14-day study of 60 dogs having prior veterinary-diagnosis OA in at least one limb joint. Two outcomes measuring the dog's quality of life were assessed: subjectively determined changes in eight behaviors associated with discomfort, and objectively determined changes in passive range of motion (PROM). BioElectronics' Model 088 device was secured near the cervical region of the dog's spine. PROM measures were taken at baseline and day 14. Behavioral measures were taken daily. Forty-nine animals completed the study. No negative side effects were reported. Average subjective discomfort scores for the treatment group (N=26) were reduced from 4.26 to 2.31 (45%) compared to no improvement in the placebo group (N=23) over the study period. Average PROM scores increased by 5.51 (4.59--6.23) degrees relative to the placebo group. Most changes occurred within the first 8 days of treatment. Osteoarthritis is the most common type of arthritis in dogs and is the most common source of chronic pain in older dogs. This is due to the constant wearing away of the cartilage from dogs running, jumping, and other continuous exercise. The prevalence of osteoarthritis can be as high as 20% in dogs more than a year old, with middle-aged and older dogs being at higher risk. dogs that are diagnosed with arthritis tend to be lethargic, have difficulty moving from a sitting or lying position, cracking joints, stiffness, muscle wastage, and visible pain. Current treatment options for arthritis are typically NSAIDs given alone or in combination with other disease-modifying agents. In recent years, chronic use of NSAIDs has been linked to numerous side effects, including gastrointestinal (GI) bleeding, and renal and hepatic dysfunction. Anti-inflammatory drugs such aspirin and ibuprofen may also result in side effects, such as GI bleeding. BioElectronics Model 088 applied at the cervical spine level, may have the potential to significantly improve the quality of life for dogs and other small domestic animals with OA. Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device into the veterinary medicine market.
お知らせ • Feb 23Bioelectronics Corporation Announces the Publication of Pilot Study ResultsBioElectronics Corporation announced the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device. The study design had patients first wear BioElectronics' Model 088 device (about 1/2 wearing the sham device and the remaining wearing the active device) on the residual part of the limb for 28 days. After 28 days, the patient began wearing the opposite device, i.e., the sham group wearing the active device, and the treatment group wearing the active device, again for 28 days. Three major measures were obtained for both phantom pain and residual pain along with a global assessment of change in both phantom and residual pain before, during, and after each 28 days. The researchers presented their findings in a series of graphs over time depending on whether the patient was wearing the sham or active device. When wearing the sham device, patients reported, on average, no change in the median phantom limb pain or pain in the residual limb. They also reported no median change in their global assessment of pain. In contrast, when the patients were wearing the active device, they reported, on average, a 40% to 50% decrease in the median measures for both average and worst residual and phantom limb pain by day 7 and this reduction continued through day 28. Moreover, a majority of patients, when wearing the active device, reported the highest level of global change in residual pain, i.e., "very much better" by day 21 and this continued through day 28. This measure on the phantom limb pain was also positive, with the majority of subjects reporting being " much better". The researchers conclude that further study is warranted given that an identified beneficial treatment effect is associated with using BioElectronics' Model 0 88 in the setting of a low-cost and low-risk intervention. Currently, there are 1.6 million people in the United States who are living with the loss of a limb. Due to the rising number of people who have diabetes, a major cause of amputations, it is estimated that the number of amputations could grow to as many as 3.6 million by 2050. More than 7 in 10 people who have had an arm or leg amputated have pain in the lost limb, which they perceive as still present. Nearly 4 in 10 have severe pain, and many also report depression and anxiety linked with phantom limb pain making it hard to sleep, work, and take part in family and social activities. People who have phantom limb pain are often prescribed medications, including opioids, but opioid medications are effective in only about half of these patients and can also have serious side effects, including the risk of addiction. Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device to address this significant unmet medical need.
お知らせ • Dec 17BioElectronics Executes Distribution Agreement with KT Health, LLC for North American Retail MarketBioElectronics Corporation announced that it has executed an OEM agreement with KT Health, LLC to bring its innovative pain management devices to encompass retail and e-commerce distribution throughout North America, as well as several additional key international markets.
お知らせ • Nov 07BioElectronics' ActiPatch Therapy To Be Marketed By DonJoy AdvantageBioElectronics Corporation announced the execution of a commercial partnership agreement with Scott Specialties Inc. to bring their innovative pain management devices to the retail consumer healthcare marketplace under the DonJoy (DJO www.djoglobal.com) Advantage product line. This commercial partnership will leverage the ActiPatch's broad indications for use and offer an active-passive treatment combination product to treat pain, increase physical functionality and improve overall quality of life. The new products will be marketed under DJO's DonJoy Advantage (DJA) line of orthopedic appliances and sold as an EME Knee Wrap and an EME Back Wrap," powered by ActiPatch".
